Elevance Health | ELV | Long at $286.00What are seeing in the healthcare and health insurance provider industry right now is destruction before a once-in-a-lifetime boom. The baby boomer generation is between 60 and 79 right now and the amount of healthcare service that will be needed to serve that population is staggering. Institutions are crushing them to get in - it's just near-term noise, in my opinion. My personal strategy is buy and hold every healthcare opportunity (i.e. NYSE:CNC , NYSE:UNH , NYSE:HUM etc).
Elevance Health NYSE:ELV just dropped heavily due to lower-than-expected Q2 2025 earnings, a cut in full-year profit guidance from $34.15-$34.85 to ~$30 EPS, and elevated medical costs in Medicaid and ACA plans. It's near-term pain (may last 1-2 years) which will highly likely lead to long-term growth. The price has touched my historical simple moving average "crash" band. I would not be shocked to see the price drop further into the $260s before a rise. However, the near-term doom could go further into the year. I am anticipating another drop to the "major crash" simple moving average band into the $190s and $220s to close out the remaining price gaps on the daily chart that occurred during the COVID crash. Not to say it will absolutely reach that area, but it's locations on the chart I have for additional buys.
Thus, at $286.00, NYSE:ELV is in a personal buy zone (starter position) with more opportunities to gather shares likely near $260 before a bounce. However, if the market or healthcare industry really turns, additional buys planned for $245 and $212 for a long-term hold.
Targets into 2028:
$335.00 (+17.1%)
$386.00 (+35.0%)
Elevance
$ELV Earnings Preview: Oversold Potential + Key Metrics AheadEarnings Estimates: Analysts forecast an EPS of $3.82 for the upcoming quarter, indicating a 32% year-over-year decline. Revenue is projected at $44.67 billion, a 5.2% increase from the same period last year.
Oversold Potential: With an oversold score of 59%, NYSE:ELV appears attractive for accumulation.
PEG Ratio: The PEG ratio stands at -0.77, suggesting undervaluation despite negative growth.
Valuation Metrics: A forward P/E of 11.03, lower than the trailing P/E of 14.14, indicates potential undervaluation.
Revenue Growth: Positive quarterly revenue growth estimates point to resilient performance.
In the previous quarter, Elevance reported an EPS of $8.37, missing the consensus estimate of $9.66, but achieved a 5.3% year-over-year revenue increase to $44.72 billion.
Guidance: In the previous quarter, Elevance Health revised its full-year 2024 adjusted EPS guidance downward to approximately $33, down from the prior estimate of $37.20, due to challenges in its Medicaid business.
Despite these hurdles, Elevance's diversified portfolio and strategic initiatives position it for potential growth.
ELV Elevance Health Options Ahead of EarningsAnalyzing the options chain and the chart patterns of ELV Elevance Health prior to the earnings report this week,
I would consider purchasing the 450usd strike price Puts with
an expiration date of 2023-10-20,
for a premium of approximately $4.95.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
A tight stop for Elevance Health Required Elevance Health NYSE:ELV - Long term positioning
Positive earnings are causing a pump in price but be careful here though. Earnings positive since April 2020, why the pump? If i was entering a long term position here i would be waiting for the bottom of the parallel channel and RSI resistance line or at least harboring some cash on the side and splitting my position.
Chart Requirements
- A retest of RSI resistance line preferred
- Ideal levels outlined on chart
- If entering here, please place a tight stop loss as there is a more ideal entry lower